ANVS

Annovis Bio, Inc.

Healthcare
Biotechnology
$48M market cap

Forecast run · Sep 14, 2026Upside rank 180 of 3,136

Model Signal

ForecastQ Daily Probabilities

67.4%

27.4%

56.3%

Analyst Consensus

Recommendation2.22/5 Buy

Last price$1.12

Price target$25.67

Implied move+2192.0%

Analysts9

ForecastQ Portfolios

ANVS is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.